A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Conditions

Prostate

What is the purpose of this trial?

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.


Participation Guidelines

Age:
Gender:
Male

Click here for detailed information about who can participate in this trial.


Sponsor:
Southwest Oncology Group (SWOG)
Dates:
09/24/2013
Last Updated:
Study HIC#:
1306012231